IMMUNOLOGICAL PROPERTIES
Pharmacotherapeutic group: live bovine vaccines against IBR, ATCvet code: QI02AD01.
To stimulate active immunity against bovine herpesvirus type 1 (BoHV-1) in cattle. The vaccine contains a BoHV-1 strain (CEDDEL strain) that is double deleted within the genes coding for the gE surface protein and the tk enzyme. The tk deletion is related to reduced viral neurotropism andreduced establishment of latency. The absence of the gene coding for the gE surface protein entails that the vaccine does not elicit antibodies to glycoprotein E of BoHV-1 (marker vaccine). This enables discrimination between cattle vaccinated with this vaccine and cattle infected with BoHV-1 field virus or vaccinated with conventional non-marker BoHV-1 vaccines. Diagnostic tools designed to detect gE antibodies should be suitable for this purpose. Animals exposed to gE surface protein will test positive (eg cattle infected with BoHV-1 field virus or vaccinated with conventional non-marker BoHV-1 vaccines) but unexposed animals will test negative (ie non-infected animals, including those vaccinated with Hiprabovis IBR Marker Live). Animals vaccinated with Hiprabovis IBR Marker live will test positive (alongside cattle infected with BoHV-1 field virus or vaccinated with conventional non-marker BoHV-1 vaccines) when samples are analysed in tests based on the identification of antibodies to any other BoHV-1 antigens.